Congenital Zika virus (ZIKV) infection results in neurodevelopmental deficits in up to 14% of
infants born to ZIKV-infected mothers. Neutralizing antibodies are a critical component of …

The inclusion of infants in the SARS-CoV-2 vaccine rollout is important to prevent severe
complications of pediatric SARS-CoV-2 infections and to limit transmission and could possibly …

Toward the goal of developing an effective HIV vaccine that can be administered in infancy
to protect against postnatal and lifelong sexual HIV transmission risks, the current pilot study …

Zika virus (ZIKV) is a newly-identified infectious cause of congenital disease. Transplacental
transfer of maternal IgG to the fetus plays an important role in preventing many neonatal …

A major challenge in developing an effective vaccine against HIV-1 is the genetic diversity
of its viral envelope. Because of the broad range of sequences exhibited by HIV-1 strains, …

Zika virus (ZIKV) infection of pregnant women is associated with congenital Zika syndrome (CZS)
and no vaccine is available, although several are being tested in clinical trials. We …

Introduction It is becoming clearer that the microbiota helps drive responses to vaccines;
however, little is known about the underlying mechanism. In this study, we aimed to identify …

Studies in animal models are essential prerequisites for clinical trials of candidate HIV vaccines.
Small animals, such as rabbits, are used to evaluate promising strategies prior to further …

Abstract Development of a human cytomegalovirus (HCMV) vaccine is a Tier 1 priority by the
National Institutes of Medicine, as HCMV is the most common congenital infection globally …

Despite success in reducing vertical HIV transmission by maternal antiretroviral therapy,
several obstacles limit its efficacy during breastfeeding, and breast-milk transmission is now the …